RecruitingNCT03099681
An Observational Study on Epithelioid Sarcoma
Epithelioid Sarcoma. An Observational Study
Sponsor
Italian Sarcoma Group
Enrollment
100 participants
Start Date
Aug 22, 2017
Study Type
OBSERVATIONAL
Conditions
Summary
Prospective Italian study aimed to provide a description of the population affected by Epithelioid Sarcoma (ES)
Eligibility
Plain Language Summary
Simplified for easier understanding
This is an observational study collecting information about patients with a rare cancer called epithelioid sarcoma — a type of soft tissue cancer — to better understand how it behaves and how patients respond to treatments.
**You may be eligible if...**
- You have been diagnosed with epithelioid sarcoma, confirmed by a tissue biopsy according to 2014 World Health Organization standards
- You are willing to sign a consent form
- You are able to attend follow-up visits and comply with study requirements
- There is no age limit — children and adults are welcome
**You may NOT be eligible if...**
- You have been diagnosed with another cancer in the past 5 years (except for non-invasive cervical cancer or certain skin cancers that were fully treated)
- You are unable to comply with study visits or follow-up requirements
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERTreatment for Epitheloid Sarcoma
Treatment Epitheloid Sarcoma according the disease guideline
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03099681
Related Trials
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT066251901 location
Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group
NCT0396783420 locations
Evaluate the Safety and Clinical Activity of HH2853
NCT0439073725 locations
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
NCT062771541 location